UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/582,345	06/09/2006	Takashi Uemori	UEMOR13	4978
	7590 10/07/200 D NEIMARK, P.L.L.C	EXAMINER		
624 NINTH ST		CALAMITA, HEATHER		
SUITE 300 WASHINGTON, DC 20001-5303			ART UNIT	PAPER NUMBER
			1637	
			MAIL DATE	DELIVERY MODE
			10/07/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/582,345	UEMORI ET AL.			
Office Action Summary	Examiner	Art Unit			
	HEATHER G. CALAMITA	1637			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 66(a). In no event, however, may a reply be time till apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	Lely filed the mailing date of this communication. (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on 10 Ju     This action is FINAL. 2b) ☐ This     Since this application is in condition for allowant closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) ☐ Claim(s) 1-9 is/are pending in the application. 4a) Of the above claim(s) 6,7 and 9 is/are withd 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-5 and 8 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or Application Papers 9) ☐ The specification is objected to by the Examine 10) ☐ The drawing(s) filed on is/are: a) ☐ access	election requirement. r. epted or b)□ objected to by the E				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date 09/26/2006.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite			

Application/Control Number: 10/582,345 Page 2

Art Unit: 1637

### **DETAILED ACTION**

#### Election/Restrictions

1. Applicants' election with traverse of Group 1 (claims 1-5 and 8) in the reply filed on July 10, 2008, is acknowledged. The traversal is on the ground(s) that all of the claims share the same corresponding special technical feature. This is not found persuasive because as discussed in the Office Action mailed June 11, 2008, the features of claims 6 and 7 are disclosed in the prior art. As such these features cannot constitute any advancement over the prior art and therefore do not constitute a special technical feature.

The requirement is still deemed proper and is therefore made *FINAL*.

# Status of Application, Amendments, and/or Claims

2. Claims 1-9 are pending. Claims 6, 7 and 9 are withdrawn as being directed to non-elected subject matter. Claims 1-5 and 8 are under examination.

## Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-5 and 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Cleuziat et al. (USPN 5,824,517).

With regard to claim 1, Cleuziat et al. teach a method for amplifying a nucleic acid, the method comprising the steps of:

A) preparing a reaction mixture

(b) a nucleic acid as a template a deoxyribonucleotide triphosphate, a DNA polymerase having a strand displacement activity, at least two chimeric oligonucleotide primers and an RNase H, wherein one of the chimeric oligonucleotide primers serves as a ladder-forming oligonucleotide primer (see col. 6 line 41 to col. 7 line 31, where, two chimeric primer, RNase H, a DNA polymerase having strand displacement activity is used. Additionally, one of the chimeric primers serves as a ladder-forming primer as this primer meets the requirements outlined in the instant specification in paragraphs 0054 and 0055. See also col. 11 lines 10 to col. 12 line 66).

wherein each chimeric oligonucleotide primer contains a ribonucleotide as well as at least one selected from the group consisting of a deoxyribonucleotide and a nucleotide analog, and the ribonucleotide is positioned at the 3' terminus or on the 3' terminal side of the primer (see the abstract and col. 6 lines 7-9)

wherein the chimeric oligonucleotide primers comprise at least a first chimeric oligonucleotide primer which is complementary to a nucleotide sequence of the nucleic acid as a template and a second chimeric oligonucleotide primer which is homologous to a nucleotide sequence of the nucleic acid as a template, (see col. 6 line 41 to col. 7 line 31 and also col. 11 lines 10 to col. 12 line 66)

wherein the ladder-forming oligonucleotide primer has a sequence complementary to a region of the nucleic acid as a template that is complementary to the first chimeric oligonucleotide primer and/or a nucleotide sequence 3' to said region and has on its 5' side, a sequence complementary to a nucleotide sequence on the 5' side of the second chimeric oligonucleotide primer which is homologous to the nucleic acid template; a nucleotide sequence of the nucleic acid as a template corresponding to a region 5' to the 5' terminus of the portion homologous to the second chimeric oligonculeotide primer; or both (see col. 6 lines 41- col. 7 line 31 and also col. 11 lines 10 to col. 12 line 66)

(B) incubating the reaction mixture for a sufficient time to generate a ladder-like amplification product under constant-temperature conditions under which specific annealing of the primer to the nucleic

Application/Control Number: 10/582,345 Page 4

Art Unit: 1637

acids as a template, a reaction of synthesizing an extended strand and a strand displacement reaction by the DNA polymerase, as well as a reaction of cleaving an extended strand by RNase H take place (see col. 6 lines 41- col. 7 line 31 and also col. 11 lines 10 to col. 12 line 66, where ladder-like products are generated necessarily because of the presence of the ladder-forming primer, as defined in the instant specification)

With regard to claim 2, Cleuziat et al. teach the nucleic acid template is RNA and the nucleic acid is treated beforehand with a dntp, a DNA polymerase having a reverse transcription activity and at least one ladder-forming oligonucleotide primer to convert the nucleic acid into a reverse transcription product (see col. 6, lines 1-40, where the template can be RNA or DNA).

With regard to claim 3, Cleuziat et al.teach wherein the reaction mixture in step (A) further contains a DNA polymerase having reverse transcription activity (see col. 6 lines 31-37)

With regard to claim 4, Cleuziat et al. teach the nucleic acid template is an mRNA (see col. 8 lines 47-56, where total nucleic acid isolation is discussed and total RNA necessarily includes mRNA)

With regard to claim 5, Cleuziat et al. teach a single DNA polymerase having reverse transcription activity and strand displacement activity (see col. 6 lines 31-37)

With regard to claim 8, Cleuziat et al. teach a method for amplifying a nucleic acid, the method comprising the steps of:

- (a) amplifying a target nucleic acid according to the method for amplifying a nucleic acid defined by claim 1 and (see citations for rejected claim 1, as they all apply here)
- (b) detecting the amplified target nucleic acid (see col. 8 line 45, where Cleuziat disclose detecting target nucleic acids).

#### Summary

4. No claims were allowable.

Application/Control Number: 10/582,345 Page 5

Art Unit: 1637

## Correspondence

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Heather G. Calamita whose telephone number is 571.272.2876 and whose e-mail address is heather.calamita@uspto.gov. However, the office cannot guarantee security through the e-mail system nor should official papers be transmitted through this route. The examiner can normally be reached on Monday through Thursday, 7:00 AM to 5:30 PM.

If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at 571.272.0782.

Papers related to this application may be faxed to Group 1637 via the PTO Fax Center using the fax number 571.273.8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to 571.272.0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see http://pair-direct.uspto.gov.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

/Heather G. Calamita, Ph.D./ Examiner, Art Unit 1637